Novo Nordisk A/S (NYSE:NVO) Shares Bought by Cavalier Investments LLC

Cavalier Investments LLC grew its position in shares of Novo Nordisk A/S (NYSE:NVO) by 4.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 23,429 shares of the company’s stock after acquiring an additional 960 shares during the quarter. Cavalier Investments LLC’s holdings in Novo Nordisk A/S were worth $2,015,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in NVO. Autumn Glory Partners LLC increased its stake in Novo Nordisk A/S by 39.9% during the third quarter. Autumn Glory Partners LLC now owns 22,671 shares of the company’s stock worth $2,699,000 after acquiring an additional 6,463 shares during the last quarter. Old Port Advisors grew its stake in shares of Novo Nordisk A/S by 4.8% in the third quarter. Old Port Advisors now owns 5,094 shares of the company’s stock valued at $607,000 after buying an additional 233 shares in the last quarter. Traynor Capital Management Inc. grew its stake in shares of Novo Nordisk A/S by 3.4% in the third quarter. Traynor Capital Management Inc. now owns 305,404 shares of the company’s stock valued at $36,364,000 after buying an additional 10,019 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Novo Nordisk A/S by 5.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 21,000 shares of the company’s stock valued at $2,500,000 after buying an additional 1,000 shares in the last quarter. Finally, Fidelis Capital Partners LLC grew its stake in shares of Novo Nordisk A/S by 107.0% in the third quarter. Fidelis Capital Partners LLC now owns 20,313 shares of the company’s stock valued at $2,351,000 after buying an additional 10,500 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $90.94 on Wednesday. Novo Nordisk A/S has a fifty-two week low of $77.82 and a fifty-two week high of $148.15. The business has a 50 day moving average price of $85.32 and a two-hundred day moving average price of $107.42. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The firm has a market cap of $408.07 billion, a PE ratio of 27.64, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.7874 per share. This represents a yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 47.72%.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on NVO shares. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BMO Capital Markets lowered their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Finally, Morgan Stanley started coverage on Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an “equal weight” rating for the company. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.